Immunodiagnosis of Neurocysticercosis: Ways to Focus on the Challenge by Esquivel-Velázquez, M. et al.
Hindawi Publishing Corporation
Journal of Biomedicine and Biotechnology




Waysto Focuson the Challenge
M. Esquivel-Vel´ azquez,P. Ostoa-Saloma, J. Morales-Montor,
R. Hern´ andez-Bello, and C.Larralde
Departamento de Immunolog´ ıa, Instituto de Investigaciones Biom´ edicas, Universidad Nacional Aut´ onoma de M´ exico (UNAM),
A.P. 70228, Ciudad Universitaria, C.P. 04510 M´ exico City, DF, Mexico
Correspondence should be addressed to C. Larralde, larralde@servidor.unam.mx
Received 1 June 2011; Revised 22 August 2011; Accepted 23 August 2011
Academic Editor: Luis I. Terrazas
Copyright © 2011 M. Esquivel-Vel´ azquez et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Neurocysticercosis (NCC) is a disease of the central nervous system that is considered a public health problem in endemic
areas. The deﬁnitive diagnosis of this disease is made using a combination of tools that include imaging of the brain and
immunodiagnostictests,butthefacilitiesforperformingthemareusuallynotavailableinendemicareas.Theimmunodiagnosisof
NCCisausefultoolthatcanprovideimportantinformationonwhetherapatientisinfectedornot,butitpresentsmanydrawbacks
as not all infected patients can be detected. These tests rely on puriﬁed or semipuriﬁed antigens that are sometimes diﬃcult to
prepare. Recent eﬀorts have focused on the production of recombinant or synthetic antigens for the immunodiagnosis of NCC
and interesting studies propose the use of new elements as nanobodies for diagnostic purposes. However, an immunodiagnostic
test that can be considered as “gold standard” has not been developed so far. The complex nature of cysticercotic disease and
the simplicity of common immunological assumptions involved explain the low scores and reproducibility of immunotests in the
diagnosis of NCC. Here, the most important eﬀorts for developing an immunodiagnostic test of NCC are listed and discussed. A
more punctilious strategy based on the design of panels of conﬁrmed positive and negative samples, the use of blind tests, and a
worldwide eﬀortisproposed inordertodevelop an immunodiagnostictestthatcan providecomparable results.Theidentiﬁcation
of a set of speciﬁc and representative antigens of T. solium and a thorough compilation of the many forms of antibody response of
humans to the many forms of T. solium disease are also stressed as necessary.
1.Introduction
Neurocysticercosis (NCC) is a disease caused by the metaces-
tode or larval form of the tapeworm Taenia solium when it
lodgesinthecentralnervoussystem(CNS)andisendemicof
the Andean area of South America, Brazil, Central America
and Mexico; China, the Indian subcontinent, and South-
East Asia; sub-Saharan Africa [1–3]. It is considered a public
health problem as it is the main cause of late-onset epilepsy
[4] and it is also the most important parasitic disease of the
nervous system [3, 5, 6]. Cysticerci may also locate elsewhere
in skeletal muscles, heart, eyes, diaphragm, tongue, and
subcutaneous tissues, causing a condition simply referred to
as cysticercosis.
NCCisadiseasediﬃculttodiagnosebasedontheclinical
picture as it presents a variety of nonspeciﬁc symptoms and
in 50% of the cases none [7]. The symptoms diﬀer according
to the location of the cysts in the brain (parenchymal or
ventricular) and the number and the state of the parasites
(vesicular, degenerating, or calciﬁed) [5, 8–12]. The severe
forms of NCC seriously impair the patients’ health and may
lead to death. Medical diagnosis of NCC is impossible on
clinical data alone. The deﬁnitive diagnose is made using
a combination of methods including images of the cysts in
the brain (by computed tomography or magnetic resonance
imaging) and immunological methods (detection of speciﬁc
antibodies or antigens). As this is a disease frequently
associated to poverty [3, 13, 14], the availability and high2 Journal of Biomedicine and Biotechnology
costs of neuroimages or sophisticated immunological assays
in endemic areas limit the diagnostic capacity [15]. An
eﬀective immunodiagnosis of NCC would be the most
practical way to facilitate medical diagnosis for millions of
poor people in endemic countries and it would also supply
sero-epidemiological studies with a low-cost indicator of
prevalence of infection. In addition, a positive immune test
would raise the clinical suspicion of early nonsymptomatic
N C Cw h i c h ,i fc o n ﬁ r m e d ,w o u l da l l o wo ﬀering early treat-
ment. Interesting advances in immunodiagnostic assays for
NCC have been made during the past few years, involving
the use of synthetic or recombinant antigens [16–29]a n d
some eﬀorts have been done to detect speciﬁc antigens or
antibodies in noninvasive ways for the patient [30–33]. Most
reports initially claim very high speciﬁcity/sensitivity scores,
sometimes even as high as 100/100%. Enthusiasm soon
calms as the methods are applied by diﬀerent laboratories,
in larger numbers of cases and in various epidemiological
scenarios of the disease [31, 34–37].
Immunodiagnosis of NCC can be done by two ways:
by identifying antibodies against cysticercal antigens, or by
identifying parasite’s antigens directly. Here is a review of the
recent studies made in the area of immunodiagnosis of NCC
and the methods used in each case are discussed.
2.Biological FactorsInvolvedin
Neurocysticercosis
Host factors as age, gender, or race are involved in the
severity of NCC (Figure 1). Age has an eﬀect upon the
numberofcysticercallesionsandonthestateofthecysticerci
in the brain (vesicular, colloidal): while vesicular cysticerci
increase with aging, colloidal cysticerci diminish without
representing an increment on severity of NCC [38]. Sexual
dimorphism has been reported in many parasitic infections
as malaria, schistosomiasis, tripanosomiasis, toxoplasmosis,
and cysticercosis [39]. The eﬀect of sex hormones upon
the immune system is evident, for example, in T. solium
cysticercosis, the prevalence of naturally infected pigs almost
doubles in castrated or pregnant pigs [40]. In general,
females generate more robust humoral and cell-mediated
immune responses than males, but males present a stronger
inﬂammatory response to infectious organisms [41]. In
NCC, females present increased levels of IL5/Il6/IL10 in
cerebrospinal ﬂuid (CSF) [42] as well as a higher leukocyte
counts than men [38] and more frequently present severe
NCC [43] which may have a relation with the location
of the cysts in the brain and with higher inﬂammatory
proﬁles in female [44]. Furthermore, females present higher
immunoglobulin levels than men to diﬀerent antigenic
challenges [45] and in seroepidemiological surveys females
show the highest anticysticerci response [46].
The genetic diﬀerences between diﬀerent populations
also play a role in infectious diseases [47–49], especially on
terms of susceptibility to disease as in the case of malaria
[50]. In NCC, some antigens from the HLA complex have
been involved in the relative risk for developing parenchymal
NCC [51], but studies of this type are scarce. A study identi-
fying genes responsible for the pleomorphic presentation of
the disease has not been done, but the eﬀect of the genetic
background upon the development of this particular disease
is clear between subjects from diﬀerent endemic areas, as
is the case of India in which single cysticercotic granuloma
(SCG) is the most frequent presentation of NCC while in
Latin America it is not [35, 52].
Furthermore, genetic variability of the parasite itself
has been described. Genetic variability of cysticerci has
been found at diﬀerent levels, from the global level (which
identiﬁed two genotypes: Asia and Africa/Latin America)
[53–57]) to the regional and the community level [58].
With all these factors involved, it is hard to ﬁnd a single
immunodiagnostic test that can detect all true NCC cases
and that can work worldwide.
3. Problems, Advances, andPerspectivesin
the ImmunodiagnosisofNeurocysticercosis
Historically, tests developed to diagnose NCC either by
detecting speciﬁc antibodies or antigens have shown that
not all cases could be detected (false negatives) and many
other cases are detected as positive (false positives) when
they are not. The ﬁrst case is related to the number, state,
and location of the cysticerci in the brain and involves
patients with degenerating, dead, or single cysticerci. The
second case involves patients with parasitic diseases closely
related to cysticercosis (as echinocococcis or hymenolepia-
sis), patients exposed to the parasite but that did not become
infected, patients with cysticercosis outside the central
nervous system and patients who once were infected but
resolved the infection without consequences. Additionally,
almost half of NCC cases are asymptomatic [12] and the
symptomatic cases present a variety of unspeciﬁc symptoms
as chronic epilepsy and headaches as the most common
[8].
Immunodiagnostic tests for NCC initially claim to have
very good sensitivity/speciﬁcity scores, but as they are being
tested by other groups, in larger number of cases and in
areas with diﬀerent degrees of endemicity the scores are
lower [31, 37, 52]. Also the scores lower because many
immunodiagnostic tests rely on puriﬁed or semipuriﬁed
antigens and the procedure of puriﬁcation is complex and
frequentlyrequiretechnicalexpertise.Thisquestion,coupled
with diﬀerences in the selection of the NCC patients and the
controlgroups,provokeslargevariationswithinandbetween
tests and low reproducibility between laboratories. The need
toﬁndnewantigensforimmunodiagnosisofNCCwhichcan
improve the diagnostic capacity of actual tests persists. These
new antigens have to be tested by various laboratories to
prove that the sensitivity/speciﬁcity maintains between tests
putting special attention on the selection of NCC patients
and controls so the results can be compared. Some eﬀorts
havebeendoneinrecentyearstotrytomakeamoreuniform
immunodiagnostic test [20, 24] and to make comparable the
results from diﬀerent tests between laboratories [16, 26, 59,
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Figure 1: Factors involved in NCC. The development of NCC depends on many factors from either the host or the parasite. The factors
aﬀectingtheimmuneresponseofthehostareparticularly importantfortheimmunodiagnosisofNCCastheymayaﬀecttheresultsbetween
individuals.
4. Detection of Antigens or Antibodies for
the Immunodiagnosis of NCC
Immunodiagnostic tests can be divided in two major groups:
the ones that use an antigenic mixture or single antigens to
try to ﬁnd antibodies against them; and the ones that use
speciﬁc antibodies to ﬁnd speciﬁc antigens in the samples.
Looking for antibodies against cysticercal antigens can
be done using a variety of samples from the human
body: serum, CSF, urine, saliva, and so forth, but a major
disadvantage of this approach is that false positives can
result as antibodies do not necessarily indicate an active
infection with viable metacestodes but a resolved one or
exposure to the parasite [61]. Another disadvantage is that
cross-reactivitymayoccurwithotherparasiticdiseases,most
commonly Echinococcus granulosus [25, 62–67], although
cross-reactivity has also been reported with other diseases
as hymenolepiasis, fasciolasis [62], toxoplasmosis [67, 68],
malaria [67], amoebiasis [67], syphilis [68], hepatitis B [68],
toxocariasis [62], cerebral tuberculosis [37, 67], mononucle-
osis [68], among others [25, 37, 65], which may be due to the
selection of bad characterized samples and not necessarily
to the fact that patients are infected with something else
than T. solium. However, the search for antibodies in samples
has the advantage that mixtures of antigens can be used (as
parasite extracts or semipuriﬁed antigens) while the search
for antigens needs to have speciﬁc antibodies against the
desired antigens but can indicate an active infection [15, 69].
When looking for antibodies against parasite antigens, the
mostfrequentlyusedsamplesareserumorCSFandthemost
common immunoglobulin is IgG as it is the predominant
antibody detected in NCC, although IgA, IgE, and IgM can
also be detected but have little value in diagnosis [13, 70],
thoughtheycanbeusedforfollow-up,asNCCpatientsshow
undetectable levels of IgG4, IgM, and IgA antibodies in saliva
afterdrugtreatment,whileantibodiesinserumpersistlonger
regardless of the subtype [33].
5. Antigens Used for Inmunodiagnosisof NC
Multiple antigens have been used for the immunodiagnosis
of cysticercosis, among them are low molecular mass (LMM)
antigens[31],excretory/secretory(ES)[30,31,71–74],crude
soluble extract (CSE) [31, 68], total saline extract [59],
antigen B [75, 76], lentil lectin glycoproteins (LLGPs) [52],4 Journal of Biomedicine and Biotechnology
vesicular ﬂuid (VF) [68, 77], membrane and scolex extracts
[68], somatic antigens [74], recombinant proteins [16–18,
20, 21, 25–28], and synthetic peptides [19, 24, 29]. The
source of these antigens has been commonly Taenia solium
(the parasite responsible for NCC) but related species as
Taenia crassiceps [5, 24, 68, 77–79], Taenia saginata [59, 80],
or Taenia taeniformis [81] have also been used as antigen
sources; and among the multiple methods used to date
for the immunodiagnosis of NCC complement ﬁxation,
agglutination, radioimmunoassays, ELISA and Western Blot
(WB) can be counted [34, 77, 80, 82, 83]. Some of these
methods are too old, but have the advantage of being cheap,
so they could be used with new antigens and yield diﬀerent
results.
Most commonly for the immunodiagnosis of NCC, se-
rum or CSF samples are used with some advantages and
disadvantages for each one. For instance, it is proposed
that the detection of antigens or antibodies in CSF is bet-
ter than in serum because there is a release of parasite an-
tigens directly to it or local production of antibodies, but
it is more diﬃcult and dangerous to obtain than serum
and requires special facilities. However, WB with LLGPs
(LLGP-WB, considered by many to be the most reliable
method for serologically detecting NCC) both samples have
no signiﬁcant diﬀerences in performance, although antigen
detection by ELISA is better in CSF than in serum, but this
test is less sensitive than LLGP-WB [69].
LLGP-WB [84]h a sas e n s i t i vi tyo f>90% and a speciﬁcity
of 100% [2]. This assay involves the separation of 7
glycoprotein antigens (50, 42–39, 24, 21, 18, 14, and 13kDa)
by SDS-PAGE and its recognition in an immunoblot by
serum of CSF antibodies. However, in recent studies mainly
in Indian patients where almost two thirds of the NCC
patients have an SCG [35, 52], LLGPs have shown to be
less sensitive than for multiple cysticerci. In these cases,
sensitivity has been reported to range between 50 and 80%
and speciﬁcity between 94 and 100% [22, 35, 85, 86]. Also
this test has been shown to be less sensitive in children than
in adults and the pattern of protein recognition also diﬀered
in these age groups (children tend to recognize the higher
molecular mass proteins while adults tend to recognize
LMM with serum or CSF antibodies) [87]p r o b a b l yd u e
to the time of infection and the antigenic stimuli. The
most common bands identiﬁed by serum antibodies are,
along with the 18 and 14kDa, the 29kDa for SCG and
the 31kDa for multiple lesions [35]. In Latin American
NCC patients, where multiple lesions are more common
than SCG, the most common recognized bands were 39–
42kDa and 21kDa [60]. So there seems to be diﬀerences
not only in the amount of antibodies produced between
SCG and multiple lesions [88, 89], but also in the antigens
recognized by these antibodies. To try to improve the
diagnosis of SCG patients, LLGPs have been unfolded and
reduced trying unmask epitopes that may detect antibodies
in these SGC patients and resulted that the unfolding of
the diagnostic proteins with urea exhibited the maximum
antibody binding and in this conformation 46% of the
patients with SGC that were serologically negative became
positive [35].
Problems like this one, or the diﬃculty to diﬀerentiate
between NCC and cysticercosis elsewhere have lead to the
search of new antigens and methods to immunodiagnose
NCC. Antigenic extracts from Taenia solium cysticerci have
been reevaluated [31, 68, 90], as well as antigens from other
related species as Taenia taeniformis [81], Taenia saginata
[59, 80]o rTaenia crassiceps [5, 24, 68, 77–79], which have
been useful for identifying new protein candidates for the
immunodiagnosis of NCC and also have shown drawbacks
as the propensity to cross-reactions which has lead to tests
with low speciﬁcity. However, the use of related species as
the ones mentioned above provide an alternative source of
parasitic antigens as there are diﬃculties to obtain Taenia
solium cysticerci from a natural infected source, even in areas
of high endemicity [78, 91]. However, the use of parasitic
extracts present many drawbacks that need to be considered
if intended for immunodiagnosis as the variation between
isolates and diﬀerences in the methods of extraction by
diﬀerent laboratories, which leads to poor reproducibility
and invalid comparisons between results.
6. Advances inthe Methods for
InmunodiagnosisofNC
New methods for the immunodiagnostic of NCC have
also been developed involving the reevaluation of common
methods with new antigens (e.g., ELISA or WB), or the use
of diﬀerent samples as urine or saliva [30, 31, 33], as they
havethe advantagethat theyarevery simple toobtain and do
not cause any harm to the patient. They are also convenient
to assay in endemic areas as facilities to obtain CSF or
serumsamplesarenotfrequentlypresent[92].Howeverwith
these samples not very good results have been obtained in
terms of sensitivity or speciﬁcity, especially with patients
with SCG, and the methods need to be validated with
well-deﬁned positive and negative NCC samples and with
samples from other parasitic diseases. In the case of urine,
sensitivity has been reported to be of 92% which decreased
to 62.5% for SCG patients when antigens were detected
withmonoclonalantibody-ELISA[32].Resultswerenotvery
good for antibody detection either by ELISA or LLGP-WB
in urine, with reported sensitivities ranging from 44 to 76%
and speciﬁcities from 33 to 66%, despite the antigen used
(ES, LMM, or CSE) [30, 31]. Saliva has been tested for the
detection of antibodies against CSE or antigen B (composed
by 2 immunologically identical polypeptides prepared by
collagen-binding method [75, 76]) with no much better
results for any of the immunoglobulins tested (IgG, IgG1,
IgG4, IgM, and IgA), although it was shown that IgG4 in
saliva could be a useful tool for patients’ follow-up after
treatment [33]. Nonetheless, these and other studies lack
the appropriate controls (well-deﬁned positive and negative
samples, and well-deﬁned samples of patients with other
infections to assess cross-reactions). Another method that
has emerged for the diagnosis of NCC, although it is not
immunologically very interesting, is the ampliﬁcation by
PCR of T. solium DNA present in the CSF of NCC patients,
with a high reported sensitivity of 96.7% [93], thoughJournal of Biomedicine and Biotechnology 5
control samples from patients with other parasitic infections
were not included. Other methods for the immunodiagnosis
of NCC have also been tried in an attempt to substitute the
LLGP-WB assay as its performance is expensive and requires
technical expertise. Among these methods is the dot blot
which is easier to perform and has shown to have sensibility
and speciﬁcity similar to ELISA [64, 67, 90, 94].
In addition, there have been eﬀorts to try to correlate
the result in an immunodiagnostic test with the location
and state of the cysticerci in the brain. An example is the
detection of the antigen HP10 in CSF, which correlates with
the location of the cyticerci in the brain: when located in
the subarachnoideal space or the ventricles, HP10 could be
detected, but when located in the parenchyma HP10 could
not be detected; and when cysts were damaged, HP10 levels
were reduced signiﬁcantly [15]. Also high antigen levels in
CSF suggest the presence of subarachnoid NCC [69]. Many
studies have reported tests that can diﬀerentiate live from
dead cysticerci by the detection of excretory/secretory (ES)
antigens in CSF or serum [71–74], or by the detection of
antibodies against a 10kDa protein from the vesicular ﬂuid
of Taenia solium [17, 25]. These studies support the idea that
infected hosts produce antibodies of diﬀerent speciﬁcities as
the cysticercus develops, degenerates, and dies because the
antigens released by the parasite in each state are diﬀerent
[72].
Many of the most recent eﬀorts in the ﬁeld of immun-
odiagnosis of NCC have centered in the production of
recombinant proteins or synthetic peptides that could pro-
vide a reliable source of antigens without depending on
obtaining cysts from naturally infected hosts. The advantage
of these antigens is that they would make comparable results
between and within laboratories as there is no need to purify
cysticercal antigens. However, synthesized or recombinant
proteins do not have the same glycosilation pattern as those
obtained directly from the parasite (recombinant proteins)
ordonothaveanyglycosilationatall(chemicallysynthesized
proteins). This often aﬀects the sensibility of the produced
protein, which is frequently assessed with sera that were
positive to the native protein, but rarely with diﬀerent
patients’ sera to assess if the produced protein could detect
more cases than the native one [16, 19–21]. A sensitivity of
95% means that the produced protein can detect 95% of the
cases that the native protein detected, though that does not
represent a real improvement in immunodiagnosis of NCC
unless it can also detect cases that the native protein could
not.
The principal protein targets to produce or synthesize
are the components of the LLGP-WB that are recognized
by NCC patients, and several of them have been already
synthesized and tested preliminarily. For instance, from the
members of the 8kDa family, Ts18var1 has been produced
in insect cells [16] as well as TsRs1, Ts18var1, and Ts18 Var3
[20]; the 14 and 18kDa proteins produced by recombination
[27]; Ts14, Ts18var1, TSRS1, and TSRS2var1 by chemical
synthesis [29], and full-length Ts18 and Ts14 by chemical
ligation [19], Ag1V1/Ag2 by recombination [26]a sw e l l
as Ts8B1, Ts8B2, Ts8B3 [18], Ts14 [27]a n da1 0 k D a
protein [17, 25]; GP50, which is not a member of the
8kDa family but it is part of the LLGPs, was produced by
recombination in bacteria and in a baculovirus expression
system [16, 21]. Other proteins outside those from LLGPs
that have also been produced or synthesized include T24
(integral membrane protein that does not bind to lentil
lectin) produced in a droshophila cell line [22]; HP6-Tsag
(oncospheraladhesionproteinofTaeniasaginata)inbacteria
and baculovirus systems with similar speciﬁcities between
the systems (93–95%), but higher sensitivity for the inactive
cases by the baculovirus protein (48–64%) [95]; peptide
NC-1 selected by phage-display [23]; peptides KETc12, 410,
and 413 synthesized from a cDNA library of T. crassiceps
[24], and recombinant TS24 and Es33 [28]. The methods
of production are varied, as well as the results and the ways
to evaluate the produced protein, some giving very good
sensitivities but in other cases, the native protein is much
better than the produced one.
Finally a very interesting approach for the diagnosis
of cysticercosis in pigs has been developed. This approach
involves the production of nanobodies (camelid-derived
single-domain antibody fragments) by recombination after
immunizing dromedaries with cisticercal antigens its eval-
uation for serodiagnosing cysticercosis in pigs. The selected
nanobodies had the advantage that did not cross-react with
other closely-related parasitic diseases as Taenia hydatigena,
Taenia saginata, Taenia crassiceps, or Trichinella spiralis,
although cross-reactivity with other parasites as Echinococcus
granulosus was not assessed. Nanobodies are heavy-chain-
only antibodies that recognize antigens as ﬁrmly as normal
antibodies do but are about one tenth their size [96].
This characteristic allows them to often recognize epitopes
that are not readily accessible to conventional antibodies
[97]. Nanobodies have been used also in the diagnosis
of trypanosomiasis [98] or malaria [99], but mostly there
are being directed to treat more eﬃciently autoimmune
diseases or cancer than commercial conventional antibody
therapies [100]. Nanobodies have beneﬁcial production and
stability properties [97] which, along with their antigen-
recognition characteristics, make them a promising tool for
the diagnosis and treatment of many diseases in which NCC
may be included, and this approach should be translated
to the NCC ﬁeld as it may provide an assay with higher
sensitivity, especially for diagnosing SCG patients which are
often negative in conventional tests, by recognizing epitopes
that are not recognized by conventional antibodies.
Despite all these eﬀorts and alternatives, a deﬁnitive
immunodiagnostic test for NCC has not been achieved. The
need to account with a more reproducible and sensitive
immunodiagnostic test than the actual ones remains, and
some studies have focused on this issue by synthesizing
antigensfromLLGPsusedinWBandotherantigens,butstill
there is the need to ﬁnd new antigens that can detect those
cases that are negative in LLGP-WB like SCG cases. Diﬀerent
protein expression systems have been tried to overcome
the problem of requiring a natural source of antigens and
the diﬃculties of purifying cysticercal antigens, but the
produced proteins lack the natural glycosilation pattern
and show diminished sensitivity than the native proteins.
New approaches to diagnose NCC should be explored, as6 Journal of Biomedicine and Biotechnology
the use of nanobodies that could result very interesting in
detecting diﬃcult cases. Developing an immunodiagnostic
test that could detect 100% of the true NCC cases and
exclude 100% of the true negative cases has been diﬃcult,
especially considering biological factors that are involved
and the many forms of cysticercosis as diﬀerences in the
genetics of the host and of the parasite, and there is still
much to do to improve the current tests. The biological
factors, especially those related to genetic diﬀerences of
the host or the parasite, that aﬀect NCC may explain
why a particular immunodiagnostic test ﬁrst reports very
high sensitivity and speciﬁcity scores that then lower as
it is being applied in diﬀerent regions and by diﬀerent
laboratories; and these factors could also make impossible
the development of a single immunodiagnostic test, but local
tests that can detect cases in a certain endemic area can be
developed.
Special attention should be paid in the cases selected to
evaluate new tests so results can be compared with other
tests, especially in the cases selected as controls (healthy indi-
vidualsandwithotherparasitic diseases)asthesearerespon-
sible for the speciﬁcity reported and an adequate selection
can assure that results can be compared between tests. Also,
attention should be put in including diﬀerent subsets of
NCC clinical types, as these diﬀerences aﬀect the amount
of antibodies or antigens that can be detected. Extrapa-
renchymal forms of NCC are associated with higher cir-
culating antigen levels and more reactive antibody bands
in LLGP-WB than intraparenchymal forms [69, 101–104].
These diﬀerences can aﬀect the estimation of the perfor-
mance of newly developed tests, so attention should be
put in the number of cases of each sub-type that are
included.
A plausible approach to identify antigens that can be
useful for the serodiagnosis of NCC is the separation in 2
dimensions of cysticercal antigens and their recognition by
hosts’ immunoglobulins. This method can give us useful
information about the diﬀerences in recognition of the par-
asite’s antigens by diﬀerent hosts (immunological diversity)
and about the antigens that are recognized by many or all
infected hosts (if there are any) to select antigens for use in
an immunodiagnostic test to detect true positive cases.
Finally, the following proposals for improving the actual
immunodiagnostic tests are made.
6.1. Proposals for Improvement. (1) T. solium disease is
present in many countries around the world and many re-
search groups are working to develop an immunodiagnos-
tic test that can detect all NCC individuals although so far
that goal has not been accomplished. Cooperation is neces-
sary to concert a worldwide eﬀort to carefully design a re-
search plan concordant with the complexities of T. solium
disease, and to develop and test in the short term with a
minimal number of options from which to select the most
proﬁcient immunodiagnosis of NCC the possibility to be
put to immediate production and general use while further
research for improvement continues.
(2) Clearing the problem of antigen cross-reactivity and
species representation is necessary to succeed in developing
an immunodiagnostic test for NCC. Puriﬁcation of anti-
gen(s) or epitopes critically certiﬁed to be exclusive of T.
solium and present in all members of a representative sample
of parasite specimens of an endemic site is mandatory. Some
likely candidates have been proposed [105], although further
researchisnecessarytodetermineiftheyfulﬁlltheconditions
mentioned above. A way of avoiding the high costs and
demanding technical skills involved in the puriﬁcation of
natural antigens is the use of those present in phage display
peptide libraries [23] or the production of recombinant
or chemically synthesized antigens [106]. Antigens present
in only T. solium but not in other Taenia species would
constitute the candidate antigen preparation (CAP).
(3) It is also necessary to study and characterize the
presumedwidespectrumofhumans’antibodyproductionin
T. solium disease in order to calibrate the candidate antigen
preparation that would include all infected individuals.
Western Blots using CAP in reaction with representative
samples of all subsets of infected individuals (regardless of
whether the parasite had established or not) if possible, or
at least of conﬁrmed cysticercosis and NCC samples, would
provide the images necessary to construct all immunological
proﬁles of the infected individuals. Computer-assisted image
analysis of WB and cluster analysis could address this
problem. The set of CAP that reacts with all or most infected
individuals in which the parasite was established would
constitute the deﬁnitive antigen preparation (DAP).
(4)Ratherthanattemptingtodevelopwaystodistinguish
each of the diﬀerent subsets of NCC disease, eﬀorts in
immunodiagnosis could focus on improving diagnosis of
NCC (to include all NCC and NCC + cysticercosis samples
and exclude cysticercosis, taeniosis, and infected but not
established samples), while for the prevalence of T. solium
disease, in whatever its form, it should only clearly distin-
guish members of the infected (established or not) from the
not infected.
Three are the classes of T. solium disease that matter the
most and perhaps require diﬀerent strategies: the contact
case, the NCC case (whether it is only NCC or NCC +
cysticercosis elsewhere), and the tapeworm carrier. For this
purpose, it is indispensable to construct representative and
certiﬁed negative and positive control panels of the samples
CSF, serum, and feces from each geographic area upon
their reaction with DAP. Certiﬁcation of the members of
cysticercosis elsewhere and of the noninfected individuals
is complicated by its need of whole-body scans in search
of cysticerci located elsewhere of CNS. Additional negative
control samples from a culturally and historically certiﬁed
community or geographic area without T. solium disease
and low in infectious diseases in general would be useful to
establish the cut-oﬀ values for immunotesting with DAP.
(5) Once the problem of antigen speciﬁcity and rep-
resentation is solved, there should be no major problem
to Immunodiagnose NCC in the CSF of a symptomatic
neurological patient nor of an intestinal tapeworm in the
feces, preferably by antigen detection (this is to distinguish
cysticercosis located elsewhere and live from dead cysticerci
in the CNS because antibodies could persist after the death
of the parasite for unknown periods of time).Journal of Biomedicine and Biotechnology 7
(6) However there would remain serious problems to
tackle for serology, the most accessible sample useful for
the detection of early nonsymptomatic NCC cases in the
general population and for epidemiological studies of T.
solium disease prevalence. The major problem for serology
in unambiguously detecting asymptomatic NCC cases is the
potential location elsewhere of the parasite (cysticercosis
elsewhere or taeniosis) that produces false-positive results
or the low reactivity of patients with few live cysticerci or
with dead cysticerci (NCC or elsewhere) that produces false-
negativeresults.Addingtopositive serologyamarkerofCNS
damage [107, 108] as a sign of CNS involvement could help
indiscriminatingNCCfromotherformsofT. solium disease.
The development of an eﬀective and deﬁnitive immun-
odiagnostic test for NCC is possible, but a series of consid-
erations and evaluations need to be addressed ﬁrst as stated
above, and a worldwide eﬀort is required to develop a test
that could be eﬀective everywhere. Nonetheless, the eﬀort
is necessary and the result would be very useful to help
eradicate this disease.
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